Creado por gina_evans0312
hace casi 11 años
|
||
Pregunta | Respuesta |
Age of host | Determines the effect of primary infection |
EBV Carriers at Risk of Cancer | Immunocompromised & genetically unlucky |
Virus Integration | Doesn't happen- remains an extrachromosomal episome |
Genome Size & Type | Large DNA virus |
Genome Stability | High- rarely mutates |
Latency | Enters this phase in some hosts- the form that causes cancers |
Avoiding Immune Surveillance- Avoid Cytotoxic T-Cell | Blocking antigen processing/presenting by phagocytes |
Avoiding Immune Surveillance- Latency | Suppression of viral gene expression that makes immune detection impossible |
Avoiding Immune Surveillance- Response Modification | EBV can modify the immune response to its detection, causing the release of inflammatory cytokines |
Source of Infection | Usually through saliva |
Site of Infection | Most commonly B cells |
CD21 | Together with CD19, it forms the B cell receptor- EBV binds to it to enter the cell |
GP350 | Used by EBV to bind to CD21, which allows it to enter the cell by endocytosis |
Viral Replication Cycle | Lytic |
Characteristic Of Lytic Replication | IgG's against viral capsid proteins |
Exit From Cell | Endocytosis, so cell isn't killed |
Viral DNA Polymerase | Responsible for copying the genome in the lytic cycle |
Products of Latency Stage | Doesn't result in EB virons, allowing it to avoid the immune system |
Length of Infection Before Latency is Activated | 3 to 6 weeks |
Host DNA Polymerase | Responsible for copying the genome in the latent phase |
¿Quieres crear tus propias Fichas gratiscon GoConqr? Más información.